Tirzepatide for Type 1 Diabetes and Obesity

This trial examines how a new treatment, tirzepatide, affects stomach emptying in individuals with Type 1 Diabetes who are overweight or obese. Researchers aim to determine if this medication, combined with acetaminophen (a common pain reliever), can better manage these conditions. Participants are divided into two groups: one receives tirzepatide and acetaminophen, while the other receives a placebo (inactive substance) and acetaminophen. Suitable candidates have had Type 1 Diabetes for at least a year, use insulin, have a BMI of 25 or more, and have not significantly changed their weight in the past three months. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

Research has shown that tirzepatide is generally well-tolerated. In earlier studies, most side effects were mild to moderate, with the most common being stomach-related issues like nausea, affecting 12-18% of participants. These symptoms were temporary and often resolved on their own.

Additionally, tirzepatide has proven safe in real-world use. People taking the drug experienced weight loss and required less insulin. However, there is a higher risk of severe low blood sugar in some cases, so careful monitoring remains important.

Researchers are excited about tirzepatide for Type 1 Diabetes and obesity because it offers a novel approach by acting as a dual agonist on the receptors for both GLP-1 and GIP, hormones involved in regulating blood sugar and appetite. This is different from current treatments, which primarily focus on insulin therapy for Type 1 Diabetes and various drugs or lifestyle changes for obesity. By targeting these specific hormone pathways, tirzepatide has the potential to improve blood sugar control and aid in weight loss more effectively and efficiently than existing options.

Research has shown that tirzepatide may aid in weight management and type 2 diabetes. It mimics hormones that regulate blood sugar and appetite. Previous users have experienced weight loss and improved blood sugar levels. For individuals with obesity, it reduces appetite, aiding weight loss. In this trial, participants will receive either tirzepatide with acetaminophen or a placebo with acetaminophen to assess its effects on weight and blood sugar in those with type 1 diabetes and obesity. Although limited information exists for type 1 diabetes, its potential impact on weight and blood sugar could be beneficial.⁶⁷⁸⁹¹⁰